Compassionate Use of Drugs and India’s Status Viz Global Status During Pandemic COVID 19

Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to progress, with more than 103 million global cases and more than 2.2 million deaths as of February 2, 2021. While the world awaits the distribution of effective vaccines, a number of pharmacologic agents have been studied for treatment of coronavirus disease 2019 (COVID-19), the syndrome caused by SARS-CoV-2. favipiravir, tocilizumab, Remdesivir, a nucleotide analogue prodrug with in vitro effects against a broad array of RNA viruses,2-4 has received considerable attention. Clinical trials assessing the effectiveness of remdesivir have yielded conflicting results; have not included a sufficient number of patients from groups most affected by COVID-19, such as Black or Latinx individuals; and have not examined the coadministration of remdesivir with other drugs. Within a few months over a thousand clinical trials of potential treatments were launched By 29 April 2020, data from two completed trials and interim data from a third large trial were made available to regulators, in support of the use of remdesivir in patients with COVID-19.